Korean J Gastroenterol.  2015 May;65(5):330-332. 10.4166/kjg.2015.65.5.330.

What Is the Long-term Effect of Helicobacter pylori Eradication on Gastric Adenoma?

• Tae CH
• Shim KN

• KMID: 2373232
• DOI: http://doi.org/10.4166/kjg.2015.65.5.330

Abstract

No abstract available.

MeSH Terms

Adenoma
Gastric Mucosa
Helicobacter Infections
Helicobacter pylori/*drug effects
Humans
*Time

Reference

References

1. Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol. 2000; 24:167–176.

2. Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut. 2002; 51:130–131.

3. Lauwers GY, Riddell RH. Gastric epithelial dysplasia. Gut. 1999; 45:784–790.

4. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust. 1985; 142:436–439.

5. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991; 325:1132–1136.

6. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325:1127–1131.

7. Suzuki S, Gotoda T, Suzuki H, et al. Morphologic and histologic changes in gastric adenomas after Helicobacter pylori eradication: a long-term prospective analysis. Helicobacter. 2015. doi: 10.1111/hel.12218. [Epub ahead of print].

8. Haruma K, Mihara M, Okamoto E, et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus-evaluation of 24-h pH monitoring. Aliment Pharmacol Ther. 1999; 13:155–162.

9. Naito Y, Ito M, Watanabe T, Suzuki H. Biomarkers in patients with gastric inflammation: a systematic review. Digestion. 2005; 72:164–180.

10. Lynch DA, Mapstone NP, Clarke AM, et al. Cell proliferation in Helicobacter pylori associated gastritis and the effect of eradication therapy. Gut. 1995; 36:346–350.

11. Shiotani A, Iishi H, Ishiguro S, Tatsuta M, Nakae Y, Merchant JL. Epithelial cell turnover in relation to ongoing damage of the gastric mucosa in patients with early gastric cancer: increase of cell proliferation in paramalignant lesions. J Gastroenterol. 2005; 40:337–344.

12. Kobayashi M, Hashimoto S, Nishikura K, et al. Magnifying nar-row-band imaging of surface maturation in early differentiated- type gastric cancers after Helicobacter pylori eradication. J Gastroenterol. 2013; 48:1332–1342.

13. Kitamura Y, Ito M, Matsuo T, et al. Characteristic epithelium with low-grade atypia appears on the surface of gastric cancer after successful Helicobacter pylori eradication therapy. Helicobacter. 2014; 19:289–295.

14. Kiyohira K, Yoshihara M, Ito M, Haruma K, Tanaka S, Chayama K. Serum pepsinogen concentration as a marker of Helicobacter pylori infection and the histologic grade of gastritis; evaluation of gastric mucosa by serum pepsinogen levels. J Gastroenterol. 2003; 38:332–338.

15. Massarrat S, Haj-Sheykholeslami A, Mohamadkhani A, et al. Pepsinogen II can be a potential surrogate marker of morpho-logical changes in corpus before and after H. pylori eradication. Biomed Res Int. 2014; 2014:481607.

16. Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010; 71:1150–1158.

17. Rugge M, Genta RM. OLGA Group. Staging gastritis: an international proposal. Gastroenterology. 2005; 129:1807–1808.

18. El-Zimaity HM, Ramchatesingh J, Saeed MA, Graham DY. Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol. 2001; 54:679–683.